[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"toxicity\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:toxicity":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,77,101,130,160,188],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100416274","phase-1-the-effects-of-scfa-supplementation-in-subjects-receiving-abdominopelvic-rt-a-randomized-controlled-study-100416274",false,"NCT04700527","The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study","LCCC2032: The Effects of Short Chain Fatty Acid Supplementation on the Quality of Life and Treatment-related Toxicities in Subjects Receiving Abdominopelvic Radiotherapy: A Randomized Controlled Study","Inclusion Criteria:\n\n* Written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information. Consent for the use of any residual material from biopsy and\u002For surgical resection (archival tissue) and serial blood draws will be required for enrollment.\n* ≥ 18 years of age on day of signing informed consent.\n* ECOG performance score ≤ 2\n* Subjects with histological or cytological evidence\u002Fconfirmation of GI, urologic or gynecologic malignancy that will be treated with minimum dose of 40Gy (equivalent dose in 2Gy per fraction or EQD2) via 3D conformal fields or IMRT to abdomen or pelvis (multimodality treatment with surgery, chemotherapy is permissible)\n* Subjects may have had prior chemotherapy or surgery.\n* Subjects deemed healthy for study inclusion by the treating physician based on the laboratory values at screening and general health status.\n* Prior cancer treatment must be completed at least 14 days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ≤ Grade 1 or baseline.\n* Females of childbearing potential must have a negative urine pregnancy test within 14 days prior to simulation. NOTE: Females are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are naturally postmenopausal for at least 12 consecutive months. Documentation of postmenopausal status must be provided.\n* Females of childbearing potential must be willing to abstain from heterosexual activity or to use 2 forms of effective methods of contraception from the time of informed consent until 14 or 28 days after treatment discontinuation. The two contraception methods can be comprised of two barrier methods, or a barrier method plus a hormonal method or an intrauterine device that meets \\\u003C 1% failure rate for protection from pregnancy in the product label.\n* Male subjects with female partners of childbearing potential must have had a prior vasectomy or agree to use an adequate method of contraception (i.e., double barrier method: condom plus spermicidal agent) starting with the first dose of study therapy through 14-28 days after the last dose of study therapy.\n* Subjects is willing and able to comply with study procedures based on the judgement of the investigator or protocol designee.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding (NOTE: breast milk cannot be stored for future use while the mother is being treated on study).\n* Prior abdominopelvic RT\n* History of inflammatory bowel disease or GI motility disorder\n* Grade 2 or higher diarrhea at baseline unless deemed by the investigator to be caused by laxatives prescribed for symptomatic partial obstruction\n* Concurrent use of histone deacetylase inhibitors (vorinostat)\n* Baseline hypernatremia defined as serum sodium concentration \\>145 mEg\u002FL\n* Creatinine clearance \\\u003C 50 mL\u002Fmin\n* Congestive heart failure\n* On a salt restricted diet for medical indications\n* Severe nut allergy\n* Active infection requiring systemic therapy.\n* Active central nervous system (CNS) metastases\n* Treatment with any investigational drug other than the drugs in this study and subjects may not be on another clinical trial.\n* Subject is receiving prohibited medications or treatments as listed in section 5.6 of the protocol that cannot be discontinued\u002Freplaced by an alternative therapy.","ALL","18 Years",{"count":19,"type":20},122,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","The purpose of this study is to assess and compare GI toxicity from RT between subjects who receive therapeutic SCFA and those who receive placebo, in hopes of identifying a safe, low-cost therapeutic to reduce GI toxicity from therapeutic or environmental radiation.",[27,28],"Toxicity","Radiation Toxicity",[30,31,32],"GI cancer","Urinary cancer","Gynecological Cancer","RECRUITING","2026-06-01",{"date":36,"type":37},"2026-06-03","ACTUAL",{"date":39,"type":37},"2023-12-15",{"date":41,"type":20},"2031-05",{"name":43,"class":44},"UNC Lineberger Comprehensive Cancer Center","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":17,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100624367","neurocognitive-deficit-after-paediatric-transplantation-understanding-the-role-of-environment-and-physical-function-100624367","NCT07408713","Neurocognitive Deficit After Paediatric Transplantation: Understanding the Role of Environment and Physical Function","The NATURE Study (Neurocognitive Deficit After Paediatric Transplantation: Understanding the Role of Environment and Physical Function)","NATURE","Inclusion Criteria:\n\n1. Recipient of allogeneic HSCT in the study period\n2. HSCT at the pediatric ward\n3. Age \\\u003C18 years at referral to HSCT\n4. Signed informed consent\n\nExclusion Criteria:\n\n1\\) Inability of legal guardian to speak and understand Danish","0 Years",{"count":56,"type":20},100,"OBSERVATIONAL","Hematopoietic stem cell transplantation (HSCT) is a potentially life-saving treatment for children with relapsed or resistant leukemia and other life-threatening hematological and hereditary disorders. In Denmark, around 25 children undergo allogeneic HSCT every year, of these approximately 85-90% survive into adulthood.\n\nThe goal of this observational study is to learn about neurocognitive outcomes in children undergoing (HSCT) and to understand which clinical, physical, and environmental factors may affect neurocognitive development during the first year after transplant. The main questions it aims to answer are:\n\nHow does neurocognitive function change from before HSCT to one year after transplantation in pediatric patients?\n\nWhich clinical, physical, and environmental factors are linked to better or worse neurocognitive outcomes?\n\nParticipants will:\n\nComplete neurocognitive tests before HSCT and at 1-year follow-up, covering intelligence, memory, attention, executive function, processing speed, and motor skills.\n\nUndergo physical tests before HSCT, at hospital discharge, at 6-months follow-up, and at 1-year follow-up, including muscle strength, mobility, endurance, balance, and cardiopulmonary fitness (only at 1-year follow-up).\n\nWear activity trackers to measure physical activity and sedentary time during hospitalization at 6 months and 1-year post-HSCT.\n\nComplete questionnaires about sleep, pain, quality of life, fatigue, family background, and exposure to outdoor and green spaces.\n\nHave medical records reviewed for treatment-related side effects, immune recovery, inflammation, and pain management.\n\nThis study will help understand how neurocognitive function develops after HSCT in children and which factors (clinical, physical, or environmental) may support better recovery and well-being.",[60,61,62,63,27,64,65,66],"HSCT","Pediatric Cancer","Pediatric Patients","Late Effect","Neurocognitive Dysfunction","Physical Function","Physical Capacity","NOT_YET_RECRUITING","2026-02-18",{"date":70,"type":37},"2026-02-20",{"date":72,"type":20},"2026-02-15",{"date":74,"type":20},"2031-12-31",{"name":76,"class":44},"Rigshospitalet, Denmark",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":45},"100265385","impact-of-fat-free-mass-in-the-carboplatin-calculated-dose-and-chemotherapeutic-toxicity-in-patients-with-advanced-nsclc-100265385","NCT02734069","Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC","Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)","Inclusion Criteria:\n\n* Diagnosis of NSCLC Stage IV (stratification according to the American Joint Committee on Cancers - 7th edition)\n* Candidates for treatment with carboplatin plus paclitaxel 1st line\n* Performance status (ECOG 0-2)\n* Laboratory studies that demonstrate adequate renal, hepatic and hematologic function (blood chemistry and blood count)\n* Normal renal ultrasound prior to initiation of treatment\n\nExclusion Criteria:\n\n* Patients with renal impairment (KDOQI 3-5)\n* Patients who do not have computed tomography study at baseline\n* Uncontrolled blood pressure (\\> 140 mmHg)\n* Uncontrolled diabetes (\\> 130 mg \u002F dL)\n* Obstruction in kidney (s) or ureter (s)\n* Dehydrated patients\n* Patients with high consumption of NSAIDs (aspirin, ibuprofen, etc.\\> 1 month)",{"count":85,"type":20},132,"This study evaluate the association of body composition (mainly free-fat mass), clinical and biochemical parameters with development of toxicity in patients under treatment with Carboplatin\u002FPaclitaxel in advanced NSCLC.",[88,89,27],"Lung Cancer","Sarcopenia",[91],"carboplatin","2025-12-17",{"date":94,"type":37},"2025-12-24",{"date":96,"type":37},"2016-02",{"date":98,"type":20},"2027-12",{"name":100,"class":44},"Instituto Nacional de Cancerologia de Mexico",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":117,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":45},"100557749","phase-2-elimination-of-ptv-margins-based-on-online-adaptive-stereotactic-radiotherapy-for-early-stage-non-small-cell-lung-cancer-or-pulmonary-oligometastases-100557749","NCT06542159","Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases","Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases: a Prospective, Randomized, Controlled Phase II Study","Inclusion Criteria:\n\n* Histologically or PET-CT confirmed untreated early-stage non-small cell lung cancer (T1-2N0M0) that is inoperable or where the patient is unwilling to undergo surgery, or PET-CT\u002Fchest CT confirmed lung oligometastases (number of metastases ≤3, single lesion diameter ≤5cm).\n* Age 18 years or older, regardless of gender.\n* ECOG performance status score of 0-2.\n* Serum hemoglobin ≥ 80 g\u002FL, platelets ≥ 100,000\u002FμL, absolute neutrophil count ≥ 1,500\u002FμL.\n* Serum creatinine ≤ 1.25 times the upper normal limit (UNL) or creatinine clearance ≥ 60 ml\u002Fmin.\n* Serum bilirubin ≤ 1.5 times UNL, AST (SGOT) and ALT (SGPT) ≤ 2.5 times UNL, alkaline phosphatase ≤ 5 times UNL.\n* FEV1 ≥ 0.5 L.\n* Normal CB6 range.\n* The patient and their family agree and sign the informed consent form.\n\nExclusion Criteria:\n\n* Tumors with bronchial invasion are excluded.\n* Any other disease or condition that contraindicates radiotherapy (e.g., active infections, within 6 months post-myocardial infarction, symptomatic heart disease including unstable angina, congestive heart failure, or uncontrolled arrhythmias).\n* Pregnant or breastfeeding women, women who have not undergone pregnancy testing, and pregnant individuals.\n* Individuals with substance abuse issues, chronic alcoholism, or AIDS.\n* Individuals with uncontrollable seizures or loss of self-control due to psychiatric disorders.\n* Individuals with a history of severe allergies or specific sensitivities.",{"count":109,"type":20},130,[24],"This study aims to explore the safety and efficacy of eliminating the PTV (planning target volume) margins based on online adaptive stereotactic radiotherapy for patients with early-stage non-small cell lung cancer (NSCLC) or pulmonary oligometastases.",[113,114,115,116,27],"Adaptive Radiotherapy","Stereotactic Body Radiotherapy","Non-small Cell Lung Cancer","Lung Oligometastases",[118,119,115,120,27],"Online adaptive radiotherapy","Stereotactic body radiotherapy","Lung oligometastases","2025-11-13",{"date":123,"type":37},"2025-11-17",{"date":125,"type":37},"2024-05-22",{"date":127,"type":20},"2028-04-21",{"name":129,"class":44},"Sun Yat-sen University",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":159},"100582999","practical-geriatric-assessment-pga-implementation-strategies-and-correlative-evaluations-pace-70-100582999","NCT06870617","Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations (PACE-70)","Practical Geriatric Assessment (PGA) Implementation Strategies and Correlative Evaluations for Older Adults With Cancer (PACE-70): A Hybrid Implementation-effectiveness Study","PACE-70","For PGA Implementation Cohort, patients must meet the following criteria:\n\n1. Age greater than or equal to 70 years.\n2. Diagnosis of advanced or metastatic solid malignancy\n3. Initiating a new line of palliative-intent systemic therapy with a prevalence of grade 3 toxicity exceeding 50%.\n\nFor Correlative Analysis Cohort, patients must additionally meet the following criteria:\n\n1. Must read and speak English and be able to fill out surveys\n2. Ability to walk independently or with the use of an assistive device (e.g., walker, cane)\n3. Consents to participate in correlative analysis cohort with Fitbit monitoring, body composition analysis, and self-report surveys\n4. Have a smartphone able to operate with the Fitbit\n\nFor PGA Implementation Cohort, there are no specific exclusion criteria other than not meeting inclusion criteria.\n\nFor Correlative Analysis Cohort, patients will be excluded if meeting any of the following criteria:\n\n1. Unable to effectively read and speak English\n2. Reliance on a wheelchair, ECOG of 3 or above, clinically bedbound, or unable to walk without assistance every day for the past 7 days (ECOG 3 is confined to bed or chair for more than 50% of waking hours)\n3. Concurrent enrollment in a therapeutic clinical trial (as clinical trials often have a substantial symptom-reporting structure). Non-therapeutic clinical trial enrollment is permitted\n4. Lack of clinician consent to approach patient","70 Years",{"count":140,"type":20},150,"The use of a geriatric assessment to inform oncologic care for older persons with cancer is an evidence-based practice that improves patient-clinician communication, reduces treatment-related toxicity, and is recommended by national guidelines. However, the implementation of a geriatric assessment can be time-consuming and burdensome, leading to suboptimal use in clinical practice. Developed and endorsed by the American Society for Clinical Oncology (ASCO), the Practical Geriatric Assessment (PGA) is designed to improve clinical usability and adoption, but its implementation in real-world settings has not been evaluated. The PACE-70 study aims to evaluate PGA implementation and resultant chemotherapy dose modification among older adults with advanced cancer treated in a community setting. An exploratory aim will evaluate how the PGA, body composition (via abdominal computed tomography scan) and step count monitoring (via FitBit) correlate with chemotherapy toxicity and other clinical outcomes.",[143,144,27],"Geriatric Assessment","Advanced Cancer",[136,146,147,148,149],"Practical geriatric assessment","body composition in cancer","step count in cancer","Start low go slow","2025-10-02",{"date":152,"type":37},"2025-10-03",{"date":154,"type":37},"2025-07-01",{"date":156,"type":20},"2026-10-01",{"name":158,"class":44},"Abramson Cancer Center at Penn Medicine",3,{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":138,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":21,"phases":170,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":187},"100519521","phase-3-implementing-geriatric-assessment-for-dose-optimization-of-cyclin-dependent-kinase-cdk-46-inhibitors-in-older-breast-cancer-patients-100519521","NCT06044623","Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4\u002F6-inhibitors in Older Breast Cancer Patients","Implementing Geriatric Assessment for Dose Optimization of CDK 4\u002F6-inhibitors in Older Breast Cancer Patients - a Pragmatic Randomized-controlled Trial (IMPORTANT Trial)","IMPORTANT","Inclusion Criteria:\n\nThe following inclusion criteria will be applied:\n\n1. Patients male or female aged at least 70 years old at the time of informed consent.\n2. Histologically or cytologically confirmed diagnosis of HR-positive (defined as estrogen-receptor ≥ 1%), HER2-negative breast cancer according to analysis of the most recent tumor specimen by local laboratory.\n3. Advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative treatment.\n4. No prior systemic treatment for advanced disease (recurrence during neo-\u002Fadjuvant endocrine therapy is allowed). A prior period of treatment with aromatase inhibitors or fulvestrant for up to 28 days from the CDK 4\u002F6-inhibitor initiation is allowed.\n5. Adjuvant treatment with CDK 4\u002F6-inhibitors is allowed provided a disease-free interval from treatment end \\>12 months.\n6. Either measurable disease or non-measurable bone only disease, but evaluable according to RECIST criteria 1.1.\n7. Written informed consent prior to any study-specific procedures.\n8. Adequate organ function as defined in the summary of product characteristics (SmPC) for the CDK 4\u002F6-inhibitors that is planned to be used.\n9. Able to swallow capsules.\n10. Able to understand and consent in English language or in native language for each participating country.\n\nExclusion Criteria:\n\nEligible patients will be excluded if they have one of the following criteria:\n\n1. Patients considered from treating physician as non-suitable for treatment with CDK 4\u002F6-inhibitors.\n2. Contraindications according to SmPC for the CDK 4\u002F6-inhibitors that is planned to be used.\n3. Presence of visceral crisis, lymphangitis carcinomatosis, or leptomeningeal carcinomatosis.\n4. History of any other cancer (except of non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years.\n5. Participating in other interventional trial.",{"count":169,"type":20},495,[171],"PHASE3","IMPORTANT study is a multicenter, open-label, prospective, randomized-controlled, non-inferiority trial with a pragmatic approach involving older patients (≥ 70 years old) with advanced hormone receptor (HR)-positive\u002Fhuman epidermal growth factor receptor 2 (HER2)-negative breast cancer, not amenable for curative treatment and without prior therapy for advanced disease, who are suitable to receive CDK 4\u002F6-inhibitors plus endocrine therapy as first line therapy. The study implements two approaches with high level of evidence, namely the use of comprehensive geriatric assessment (CGA) approach in treatment decision making and the use of CDK 4\u002F6-inhibitors as the initial treatment of choice, to investigate whether a common clinical practice (starting dose reduction of CDK 4\u002F6-inhibitors in older patients) with evidence of low certainty can be standardized using a more individualized-based approach.\n\nOn the basis of baseline CGA assessment, patients will either receive full dose of CDK 4\u002F6-inhibitors plus endocrine therapy (if patients are fit according to CGA) or be randomized to full dose vs. reduced initial dose of CDK 4\u002F6-inhibitors (if vulnerable or frail according to CGA). The study hypothesis is that adjusting the dose according to vulnerability will allow patients to tolerate treatment better without jeopardizing the treatment efficacy.\n\nThis project has received funding from the European Union's HORIZON 2022 research and innovation actions supporting the implementation of the Mission on Cancer under grant agreement No 101104589.",[174,175,176,27,177],"Metastatic Breast Cancer","Advanced Breast Cancer","Quality of Life","Older Patients","2024-11-15",{"date":180,"type":37},"2024-11-19",{"date":182,"type":37},"2024-04-01",{"date":184,"type":20},"2029-05-31",{"name":186,"class":44},"Region Örebro County",12,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":195,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":198,"conditions":199,"keywords":205,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":45},"100555454","plasticizer-exposure-and-its-consequences-on-health-100555454","NCT06512298","Plasticizer Exposure and Its Consequences on Health","PEACH","TDTM:\n\n* Inclusion: Adult, homozygous ß-Thalassemia Major, transfusion dependency.\n* Exclusion: Plastic implants, chronic infectious disease, pregnancy.\n\nThalassemia Intermedia\u002FMinor:\n\n* Inclusion: Adult, homozygous\u002Fheterozygous ß-Thalassemia Intermedia\u002FMinor\n* Exclusion: Plastic implants, chronic infectious disease, pregnancy, transfusion dependency\n\nHealthy adults:\n\n* Inclusion: Adult\n* Exclusion: Chronic disease, plastic implants, infectious disease, pregnancy, anemia, medication-, drug-, or alcohol-abuse\n\nGlioma patients:\n\n* Inclusion: Adult, high\u002Flow-grade glioma, tumor larger then 3cm, resection with access to the ventricular system\n* Exclusion: Large intraventricular hemorrhage, plastic implants, infectious disease\n\nICU patients:\n\n* Inclusion: Adult, brain hemorrhage, external CSF drain from ventricle\n* Exclusion: intraventricular hemorrhage, plastic implants, ECMO, hemodialysis, infectious disease\n\nPatients undergoing diagnostic lumbar-puncture:\n\n* Inclusion: Adult, diagnostic CSF sampling, outpatient setting\n* Exclusion: Ventricular hemorrhage, plastic implants, infectious disease",true,{"count":197,"type":20},120,"Plasticizers are chemicals commonly found in many everyday items, from food packaging to medical equipment. Although they are pervasive in our daily lives, researchers still don't have a clear picture of their long-term effects on human health. Evidence suggests that these substances might disrupt various biological functions such as the immune system, the balance of gut bacteria, hormone regulation, and brain processes. While some studies have linked plasticizer exposure to health issues, definitive data from human studies are still lacking.\n\nThe PEACH study aims to bridge these knowledge gaps by investigating how plasticizers affect human health. The study focuses on understanding how these chemicals are absorbed, distributed, and accumulated in the body across different groups of patients. The investigators are particularly interested in how plasticizers influence gut microbiota and the functionality of immune cells, as well as their effects on neurotransmitters involved in brain function.\n\nA combination of patient data, systems biology, and laboratory models will be used to thoroughly assess the biological impacts of plasticizers. Advanced techniques such as mass spectrometry will aid in studying toxicokinetic properties, sequencing technologies will be used to examine immune effects, and radiouptake assays will be employed to explore interactions with neurotransmitter transport. This comprehensive methodology will provide new insights into the effects of both short-term and long-term exposure to plasticizers.\n\nThe PEACH study introduces innovative methods to the field, aiming to create a robust model for understanding how plasticizer compounds behave in the human body. It employs state-of-the-art techniques to assess the dynamics of these chemicals, marking a significant advancement in environmental health research.",[200,201,202,203,204,27],"Beta-thalassemia","Glioma","Healthy Controls","Transfusion-dependent Beta-Thalassemia","Intracranial Hemorrhages",[206,207,208,209,210,211,212,213,214],"Plasticizer","Transfusion","Systems Biology","Immunology","Microbiome","Neuropharmacology","Pharmacokinetics","Pharmacodynamics","Exposomics","2024-07-22",{"date":217,"type":37},"2024-07-24",{"date":219,"type":20},"2024-10-01",{"date":221,"type":20},"2027-09-30",{"name":223,"class":44},"Medical University of Vienna"]